A vaccine against malaria in the sights of BioNTech

The promising messenger RNA technology will be applied to develop a vaccine against malaria, said the German laboratory BioNTech, which has developed with Pfizer a vaccine against Covid-19.

“BioNTech intends to develop the first mRNA vaccine for the prevention of malaria”, which will be produced on the African continent, the laboratory said in a statement.

“The probability of success is high”, argued Ugur Sahin, director and co-founder of BioNTech, a pioneering laboratory in mRNA research.

The studies, launched by the end of 2022, will take place in Africa and “other regions where malaria is widespread”, but also in Germany within the framework of this program supported by the World Health Organization, the Union European Union and the African Union Center for Disease Prevention and Control (Africa CDC).

Caused by a parasite transmitted by mosquitoes, malaria remains a formidable infectious disease, particularly in Africa, causing around 400,000 deaths per year.

BioNTech is currently working on vaccines against nine infectious diseases and is working on 15 cancer treatment programs, with results expected in the coming years.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.